- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02676531
Walking Meditation Exercise in Breast Cancer Patients
9. april 2018 oppdatert av: Assoc. Prof. Dr.Daroonwan Suksom, Chulalongkorn University
Effects of Walking Meditation on Vascular Function in Breast Cancer Patients Receiving Anthracyclines Chemotherapy
This study is to evaluate the effects of Walking Meditation on vascular function in breast cancer patients receiving Anthracyclines chemotherapy
Studieoversikt
Detaljert beskrivelse
Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation.
The subjects will perform walking while listening to the sound "Budd" and "Dha" and squeeze rubber balls according to the sound in order to practice mindfulness while walking.
In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set.
In both phases of the training, the frequency of Walking Meditation training is three times a week.
Studietype
Intervensjonell
Registrering (Faktiske)
30
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Bangkok
-
Pathum Wan, Bangkok, Thailand, 10330
- Faculty of Sports Science, Chulalongkorn University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
35 år til 70 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- The inclusion criteria included stage 1-2 of Breast cancer patients after an operation with or without Hormone Receptor Positive and HER2 Positive.
- All participants will be planned to use Anthracyclines chemotherapy in next 1 month by oncologist.
- All participants did not participate in any exercise training in the past 6 months
- All participants are free from acute or chronic renal failure, Heart Failure, Myasthenia gravis, pregnancy and history of smoke.
Exclusion Criteria:
1. Participants will be excluded if they dropped out or completed less than 80% of the training schedule.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Walking Meditation
Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation.
The subjects will perform walking while listening to the sound "Budd" and "Dha" and squeeze rubber balls according to the sound in order to practice mindfulness while walking.
In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set.
In both phases of the training, the frequency of Walking Meditation training is three times a week.
|
Walking meditation exercise program
|
Ingen inngripen: No Walking meditation
keep regular activities, sedentary life style.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change from baseline in vascular reactivity
Tidsramme: baseline, up to 12 weeks
|
Vascular reactivity or brachial artery flow-mediated dilatation (FMD) will be assessed with the ultrasound equipment (CX50, Philips, USA), using the blood occlusion technique on the forearm.
The brachial artery will be illustrated above the antecubital fossa in the longitudinal plane.
Brachial FMD will be measured at resting and the cuff placed around the forearm will be inflated to 50 mmHg above systolic blood pressure for 5 minutes and then deflated for 5 minutes of recovery.
FMD will be calculated from the formula FMD= (D2-D1) x100/D1 when D1 is the brachial artery diameter at baseline, D2 is the maximal post-occlusion brachial artery diameter.
|
baseline, up to 12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change from baseline in Intima-Media Thickness: IMT
Tidsramme: baseline, up to 12 weeks
|
Intima-Media Thickness will be assessed with the ultrasound equipment (CX50, Philips, USA).
|
baseline, up to 12 weeks
|
Change from baseline in Peripheral arterial stiffness
Tidsramme: baseline, up to 12 weeks
|
Pulse wave velocity (brachial-ankle PWV) measurement will be assessed by using Omron Colin VP1000.
|
baseline, up to 12 weeks
|
Change from baseline in venous blood flow
Tidsramme: baseline, up to 12 weeks
|
Venous blood flow will be assessed with the ultrasound equipment (CX50, Philips, USA).
The Basilic vain will be illustrated in the longitudinal plane.
Venous blood flow will be measured at resting and squeezing hand for 3 minutes and 5 minutes of recovery.
Venous blood flow will be calculated from the formula CSA x V when CSA is the cross sectional area of Basilic vain, V is the velocity in vessel.
|
baseline, up to 12 weeks
|
Change from baseline in blood chemistry
Tidsramme: baseline, up to 12 weeks
|
|
baseline, up to 12 weeks
|
Change from baseline in Maximal oxygen consumption
Tidsramme: baseline, up to 12 weeks
|
Maximal oxygen consumption (VO2max) will be assessed by Bruce Ramp Protocol for treadmill test with Stationary Gas Analyzer (Vmax™ Encore 29 system, Yorba Linda, CA).
|
baseline, up to 12 weeks
|
Change from baseline in Cardiac output and stroke volume
Tidsramme: baseline, up to 12 weeks
|
Cardiac output and stroke volume will be measured by using Physioflow (PF07 enduro).
|
baseline, up to 12 weeks
|
Change from baseline in Body Mass Index (BMI)
Tidsramme: baseline, up to 12 weeks
|
Body Mass Index (BMI) will be measured using Body Composition Analyzer (Model ioi 353, Jawon Medical Co. Ltd., Korea). BMI will be calculated by dividing weight in kilograms by height in metres squared. Unit of BMI is kg/m2. |
baseline, up to 12 weeks
|
Change from baseline in stress indicators
Tidsramme: baseline, up to 12 weeks
|
Serum cortisol will be measured with cortisol kit.
|
baseline, up to 12 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. november 2015
Primær fullføring (Faktiske)
1. november 2017
Studiet fullført (Faktiske)
1. desember 2017
Datoer for studieregistrering
Først innsendt
17. januar 2016
Først innsendt som oppfylte QC-kriteriene
5. februar 2016
Først lagt ut (Anslag)
8. februar 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
10. april 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
9. april 2018
Sist bekreftet
1. april 2018
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SPSC-5
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken